Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model

被引:34
作者
Kumaki, Yohichi [2 ]
Ennis, Jane [1 ]
Rahbar, Ramtin [1 ]
Turner, Jeffrey D. [1 ]
Wandersee, Miles K. [2 ]
Smith, Aaron J. [2 ]
Bailey, Kevin W. [2 ]
Vest, Zachary G. [2 ]
Madsen, Jason R. [2 ]
Li, Joseph K. -K. [3 ]
Barnard, Dale L. [2 ]
机构
[1] Defyrus Inc, Toronto, ON M4W 3E2, Canada
[2] Utah State Univ, Inst Antiviral Res, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA
[3] Utah State Univ, Dept Biol, Logan, UT 84322 USA
基金
美国国家卫生研究院;
关键词
Interferon; mDEF201; SARS; Treatment; Prophylaxis; ACUTE RESPIRATORY SYNDROME; IN-VITRO; SYNDROME CORONAVIRUS; SPIKE PROTEIN; INFECTION; INHIBITION; VIRUS; REPLICATION; INDUCTION; THERAPY;
D O I
10.1016/j.antiviral.2010.11.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Interferons (IFNs) are a first line of defense against viral infection. Herein we describe the use of an adenovirus vectored mouse IFN alpha gene (mDEF201) as a prophylactic and treatment countermeasure in a SARS-CoV-infected BALB/c mouse model. Complete survival protection was observed in mice given a single dose of mDEF201 administered intranasally 1, 3, 5, 7, or 14 days prior to lethal SARS-CoV challenge (p < 0.001), and body weights of these treated mice were unaffected by the challenge. In addition, low doses of mDEF201 protected lungs in a dose dependent manner as measured by a reduction in gross pathology. Intranasal treatment with mDEF201 ranging from 10(6) to 10(8) PFU significantly protected mice against a lethal SARS-CoV infection in a dose dependent manner up to 12 h post infection (p < 0.001). The data suggest that mDEF201 is a new class of antiviral agent further development as treatment for SARS-CoV infections. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 51 条
[1]   RNA-dependent RNA polymerases, viruses, and RNA silencing [J].
Ahlquist, P .
SCIENCE, 2002, 296 (5571) :1270-1273
[2]   Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs [J].
Anand, K ;
Ziebuhr, J ;
Wadhwani, P ;
Mesters, JR ;
Hilgenfeld, R .
SCIENCE, 2003, 300 (5626) :1763-1767
[3]  
Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275
[4]  
BARNARD DL, 2009, ANT RES STRAT ANT, P209
[5]   Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-α protein therapeutic [J].
Bell, Stacie J. ;
Fam, Christine M. ;
Chlipala, Elizabeth A. ;
Carlson, Sharon J. ;
Lee, Ji I. ;
Rosendahl, Mary S. ;
Doherty, Daniel H. ;
Cox, George N. .
BIOCONJUGATE CHEMISTRY, 2008, 19 (01) :299-305
[6]   The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon [J].
Blatt, LM ;
Davis, JM ;
Klein, SB ;
Taylor, MW .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (07) :489-499
[7]   Severe acute respiratory syndrome coroavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides [J].
Bosch, BJ ;
Martina, BEE ;
van der Zee, R ;
Lepault, J ;
Haijema, BJ ;
Versluis, C ;
Heck, AJR ;
de Groot, R ;
Osterhaus, ADME ;
Rottier, PJM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (22) :8455-8460
[8]  
Brassard DL, 2002, J LEUKOCYTE BIOL, V71, P565
[9]   Therapeutic and prophylactic potential of small interfering RNAs against severe acute respiratory syndrome - Progress to date [J].
Chang, Zhijie ;
Babiuk, Lorne A. ;
Hu, Jim .
BIODRUGS, 2007, 21 (01) :9-15
[10]   In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds [J].
Chen, F ;
Chan, KH ;
Jiang, Y ;
Kao, RYT ;
Lu, HT ;
Fan, KW ;
Cheng, VCC ;
Tsui, WHW ;
Hung, IFN ;
Lee, TSW ;
Guan, Y ;
Peiris, JSM ;
Yuen, KY .
JOURNAL OF CLINICAL VIROLOGY, 2004, 31 (01) :69-75